Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients

Egymedicalpedia100 enrolled

Overview

Psoriasis vulgaris is associated with significant comorbidity including depression, increased risk of cardiovascular events, diminished quality of life, as well as overall increased mortality. Moreover, concomitant psoriatic arthritis is present in up to 40% of psoriasis patients or will develop in the future. To enhance quality of life and potentially lower the risk of concomitant disease in psoriasis patients, effective treatment of this immune-mediated systemic inflammatory disease is required

Psoriasis vulgaris is associated with significant comorbidity including depression, increased risk of cardiovascular events, diminished quality of life, as well as overall increased mortality. The cytokine tumor necrosis factor (TNF)-related weak inducer of apoptosis (TWEAK), in cooperation with its sole receptor, Fn14, is involved in miscellaneous biological and pathological processes . The main role of TWEAK is in the induction of pro-inflammatory cytokines and chemokines. The upregulation of TWEAK and Fn14 occurs in many human skin disorders, including cutaneous lupus erythematosus, bullous pemphigoid, and dermatomyositis . There is a lack of studies examining the role of TWEAK in patients with psoriasis or psoriatic arthritis. The introduction of anti-tumor necrosis factor-α inhibitors (anti-TNF agents) has significantly improved outcomes among patients with PsA but a proportion of patients have an inadequate response or poor tolerability to these agents. Adalimumab treatment continuation in routine clinical practice may lead to benefits for remission and low disease activity among patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis who did not achieve their treatment goals at 12 weeks, according to recent findings. Methotrexate (MTX)was approved for the treatment of psoriasis by the US Food and Drug Administration (FDA). At present, the drug is indicated for the treatment of practically all forms of moderate or severe psoriasis, including psoriatic arthritis .

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Plaque Psoriasis

Interventions

AdalimumabDRUG

To suggests the role of TWEAK and the effectiveness of different treatments like adalimumab and methotrexate in managing plaque psoriasis and psoriatic arthritis.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients of both sexes with psoriasis vulgaris and Psoriatic arthritis. * Active PsA with three or more tender and swollen joints and met the CASPAR, despite previous treatment with NSAIDs, DMARDs or anti-TNFs Exclusion Criteria: * Previously received biologic immunomodulating agents, except for those targeting TNF * Previously been treated with three or more different TNF inhibitors * Active, ongoing inflammatory diseases other than PsA * Active TB (patients with latent TB had to commence treatment for latent TB before study entry) * A history of hepatitis B or C, human immunodeficiency virus, or any active systemic infection within the 2 weeks before baseline * History of ongoing, chronic or recurrent infections, or evidence of active TB infection * History of malignancy within the past 5 years (except for basal cell carcinoma or actinic keratosis that has been treated with no evidence of recurrence in the past 3 months, in situ cervical cancer or non-invasive malignant colon polyps that had been removed) * Underlying metabolic, hematological, renal, hepatic, pulmonary, neurological, endocrine, cardiac, infectious or gastrointestinal conditions which, in the opinion of the investigator, immunocomprimised the patient and/or placed the patient at unacceptable risk for participation * Pregnant or nursing (lactating) women and women of child-bearing potential unwilling to use effective contraception during the study and for 16 weeks after stopping treatment

Locations (1)

South Valley Hospitals

Qina, Egypt

Outcomes

Primary Outcomes

Treatment of psoriasis vulgaris and psoriatic arthritis

to see the efficacy of drug study in improving the prognosis of patients with psoriasis vulgaris and psoriatic arthritis.

Time frame: 1 year

Secondary Outcomes

Evaluation of serum TWEAK

To detect the correlation between serum TWEAK the PASI score and the ACR score pre and post Methotrexate and Adalimumab therapy

Time frame: 1 year

Central Contacts

Eisa Mohamed Hegazy, Professor

CONTACT

+201094337795 eisa_mohamed4152@med.svu.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.